CLOV - Clover Health Investments, Corp.
WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.
Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.
Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation.
Clover Health Investments, Corp. (CLOV) Q2 2026 Earnings Call Transcript
Clover Health Investments NASDAQ: CLOV reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures.
Business Highlights: Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth Improved Full Year 2026 guidance across all metrics Increasing confidence for 2027 outlook, supported by strong cohort development, continued clinical engagement, and the added flexibility of a 4.5 Star payment year Financial Results: Second quarter 2026 GAAP Net Income of $28 million, an improvement of $39 million year-over-year Second quarter 2026 Medicare Advantage membership of 157,309, up 48% year-over-year, and Total revenues of $743 million, up 56% year-over-year Second quarter 2026 Consolidated Gross Profit of $153 million, up 54% year-over-year, and Adjusted EBITDA of $41 million, up 139% year-over-year Improved Full Year 2026 Guidance: Average Medicare Advantage membership of 156,000 - 158,000, representing 47% growth year-over-year at the midpoint Total revenues between $2.92 billion and $3.00 billion, representing 54% growth year-over-year at the midpoint Consolidated Gross Profit between $525 million and $555 million, representing 52% growth year-over-year at the midpoint Adjusted EBITDA profitability between $70 million and $85 million GAAP Net Income between $20 million and $35 million WILMINGTON, Del., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the second quarter 2026.
Clover Health (NASDAQ:CLOV) has spent years as a speculative bet on a technology-led Medicare Advantage model.
The disposition involved 62,711 shares at a weighted average price of $4.67 per share, totaling ~$292,860 in transaction value. The transaction represented 0.65% of the executive's direct equity holdings in the healthcare firm.
WILMINGTON, Del., July 22, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 8:30 a.m.
Clover Health Investments said in a regulatory filing on Friday that it detected unusual login activity on some of its information systems on July 4 and later found a hacker had gained access to three employee accounts through social engineering.
WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026.
SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or “Clover Health”), and a leading AI-powered physician enablement platform, today released findings within the whitepaper “Clinical Excellence in Continuity of Care: A Real-World Analysis of Counterpart Assistant's Role in Post-Hospitalization Follow-up.” The whitepaper examines the relationship between CA use by primary care physicians (“PCPs”) and performance on high-risk care transition outcomes, including two HEDIS®1 quality measures within Clover Health's Medicare Advantage population: Transitions of Care (“TRC”) and Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (“FMC”).
CEO Andrew Toy sold 313,476 shares of Common Stock for a transaction value of ~$1.67 million as of July 1, 2026. This transaction represented 3.16% of Toy's direct holdings, reducing direct ownership to 9,609,825 shares.
Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.
Clover Health Investments Corp. (NASDAQ:CLOV) shares are extending yesterday's 18.9% surge Thursday, after a court-ordered Medicare Star Rating upgrade jumped its PPO plan from 3.5 to 4.5 Stars.
This healthcare technology company focused on Medicare Advantage plans saw a notable insider sale following a year of strong stock gains.
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
CLOV posts 62% revenue growth in Q1 as Medicare Advantage membership surges and AI-driven care initiatives boost profitability.